Phibro Animal Health shares surge 20.15% intraday after Q2 2026 earnings and sales beat forecasts, driven by 21% revenue growth.

Phibro Animal Health surged 20.15% intraday following robust fiscal Q2 2026 results, including adjusted earnings of $0.87 per share (up from $0.55 a year earlier) and a 21% year-over-year revenue increase driven by its animal health segment. The stock also reached a 52-week high of $46.95 during the week, reinforcing investor optimism. Multiple reports highlighted the company’s earnings and sales outperformance, with international summaries emphasizing a near-28% beat on expectations and strong operational growth. The intraday rally aligns directly with these positive financial results, which underscore Phibro’s improved performance and market confidence.